Pharmac is proposing to widen access to a medicine used in the treatment of chronic heart failure.
The medicine, empagliflozin, would be available to people who have chronic heart failure with reduced ejection fraction – about half of all people with chronic heart failure.
Pharmac director of pharmaceuticals Geraldine MacGibbon says empagliflozin is a medicine that can give people more time with their loved ones and lessens the time spent in hospital.
Exploring lived experience provides insights into the multiple ways that lack of affordability prevents access to medicines: directly, through interaction with other barriers to access including transport, by damaging trust and reducing acceptability of services, and by making participants less able to deal with mistakes made by health professionals.
General Practitioners Aotearoa opposes the Government’s recent decision to fund specific smoking cessation products, namely vaping kits. Read...
Health New Zealand – Te Whatu Ora’s executive team is set to change as new Health Minister Simeon Brown says he believes a refreshed line-up is necessary to ensure the entity’s focus is centred on the Government’s health targets. Read...
HEALTH SERVICES AND SYSTEMS
EQUITY
Exploring the impacts of the health system on minorities within the population, notably including Māori, Pacifica, Asians and LGBTQI.
DRUGS, DEVICE AND DIAGNOSTICS
PUBLIC HEALTH
DIGITAL HEALTH
TE TIRITI